Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Multicenter, National, Open-Label Study of Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)

NCT00840346 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT00840346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00840346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Multicenter, National, Open-Label Study of Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)
Lead sponsor
PETHEMA Foundation
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2009
Completion date
December 31, 2018
Enrollment
46 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloblastic leukaemia